First Isolates of OXA-48-Like Carbapenemase-Producing Enterobacteriaceae in A Specialized Cancer Center
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: OXA-48-like carbapenemases have been found in a growing and varied number of carbapenemase-producing Enterobacteriaceae (CPE) isolates, and they are spreading to several countries. Although this oxacillinase leads to weak resistance to carbapenems without affecting broad-spectrum cephalosporin activity, when they are associated with other resistance mechanisms, the level of resistance to these antibiotics may be significantly higher. This weak resistance against carbapenems and cephalosporins, along with the absence of other resistance mechanisms, could render OXA-48-like harboring isolates undetected in the laboratory routine. In addition, the lack of a specific screening test for this enzyme complicates the detection of these isolates. This report characterizes the first isolates of OXA-48-like CPE detected in our laboratory. Materials and methods: The study was carried out at the Instituto Nacional de Enfermedades Neoplasicas, Lima - Peru, between March and December 2021. OXA-48-like CPE isolates were detected as part of the routine microbiological study, and clinical data were obtained by reviewing medical records. The automated microbiological system provides the bacterial identification and antimicrobial susceptibility profile by the dilution method. Additionally, the column chromatography test is used to detect carbapenemase enzymes, including OXA-48-like. Finally, the molecular identification of the OXA-48-like enzyme was carried out by Polymerase Chain Reaction PCR amplification for the blaOXA-48-like. Results: Seven OXA-48-like CPE strains were isolated. Notably, in all cases, the automated system issued a minimum inhibitory concentration (MIC) of ≥1 ug/mL for ertapenem and a MIC of >64/4 ug/mL for piperacillin/tazobactam. In addition, resistance category to imipenem and meropenem was found (2/7), at least one indeterminate category for any of these carbapenems (5/7), and other serine β-lactamases such as Extended-spectrum beta-lactamases (3/7) and AmpC (3/7). The immunochromatographic study confirmed the presence of the OXA-48-like enzyme in all isolates, while class A and class B were ruled out for them. Finally, the multiplex PCR, for the five isolates that could be recovered, showed amplification for carbapenemase OXA-48-like, while none of the other carpabemases was amplified for class A or class B carbapenemase genes. Conclusion: We confirm the emergence of OXA-48-like CPE isolates in our cancer center and highlight the need to implement surveillance and detection measures of these strains, for controlling their dissemination. We found practical and inexpensive methodologies for the detection of OXA-48-like CPE: (1) the finding of resistance to ertapenem and piperacillin/tazobactam in the antibiogram in the absence of class A and B carbapenemases, for screening and (2) immunochromatographic study, for confirmation.
Abstract
Background: OXA-48-like carbapenemases have been found in a growing and varied number of carbapenemase-producing Enterobacteriaceae (CPE) isolates, and they are spreading to several countries. Although this oxacillinase leads to weak resistance to carbapenems without affecting broad-spectrum cephalosporin activity, when they are associated with other resistance mechanisms, the level of resistance to these antibiotics may be significantly higher. This weak resistance against carbapenems and cephalosporins, along with the absence of other resistance mechanisms, could render OXA-48-like harboring isolates undetected in the laboratory routine. In addition, the lack of a specific screening test for this enzyme complicates the detection of these isolates. This report characterizes the first isolates of OXA-48-like CPE detected in our laboratory. Materials and methods: The study was carried out at the Instituto Nacional de Enfermedades Neoplasicas, Lima - Peru, between March and December 2021. OXA-48-like CPE isolates were detected as part of the routine microbiological study, and clinical data were obtained by reviewing medical records. The automated microbiological system provides the bacterial identification and antimicrobial susceptibility profile by the dilution method. Additionally, the column chromatography test is used to detect carbapenemase enzymes, including OXA-48-like. Finally, the molecular identification of the OXA-48-like enzyme was carried out by Polymerase Chain Reaction PCR amplification for the blaOXA-48-like. Results: Seven OXA-48-like CPE strains were isolated. Notably, in all cases, the automated system issued a minimum inhibitory concentration (MIC) of ≥1 ug/mL for ertapenem and a MIC of >64/4 ug/mL for piperacillin/tazobactam. In addition, resistance category to imipenem and meropenem was found (2/7), at least one indeterminate category for any of these carbapenems (5/7), and other serine β-lactamases such as Extended-spectrum beta-lactamases (3/7) and AmpC (3/7). The immunochromatographic study confirmed the presence of the OXA-48-like enzyme in all isolates, while class A and class B were ruled out for them. Finally, the multiplex PCR, for the five isolates that could be recovered, showed amplification for carbapenemase OXA-48-like, while none of the other carpabemases was amplified for class A or class B carbapenemase genes. Conclusion: We confirm the emergence of OXA-48-like CPE isolates in our cancer center and highlight the need to implement surveillance and detection measures of these strains, for controlling their dissemination. We found practical and inexpensive methodologies for the detection of OXA-48-like CPE: (1) the finding of resistance to ertapenem and piperacillin/tazobactam in the antibiogram in the absence of class A and B carbapenemases, for screening and (2) immunochromatographic study, for confirmation.
참고문헌 (33)
- Falagas ME, "Deaths attributable to carbapenemresistant enterobacteriaceae infections", Emerg Infect Dis, 20, pp.1170~1175 (2014)
- Seo Hyeonji, "Risk Factors for Mortality in Patients with Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae and Escherichia coli bacteremia", Infection and Chemotherapy, 53(3), pp.528~538 (2021), 대한감염학회[DOI]
- Mairi A, "OXA-48-like carbapenemases producing Enterobacteriaceae in different niches", Eur J Clin Microbiol Infect Dis, 37, pp.587~604 (2018)
- Navarro-San Francisco C, "Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae : a major clinical challenge", Clin Microbiol Infect, 19, pp.E72~E79 (2013)
- Lutgring JD, "Phenotypic and genotypic characterization of Enterobacteriaceae producing Oxacillinase-48-like carbapenemases, United States", Emerg Infect Dis, 24, pp.700~709 (2018)
- Pitout JDD, "The global ascendency of OXA-48-type carbapenemases", Clin Microbiol Rev, 33, pp.e00102~19 (2019)
- Performance standards for antimicrobial susceptibility Testing. 30th ed, "Clinical and Laboratory Standards Institute (CLSI)", CLSI, ~, pp.CLSI supplement M100 (2020)
- Poirel L, "Multiplex PCR for detection of acquired carbapenemase genes", Diagn Microbiol Infect Dis, 70, pp.119~123 (2011)
- Nagano N, "First report of OXA-48carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Japan from a patient returned from Southeast Asia", Jpn J Infect Dis, 66, pp.79~81 (2013)
- Hartl R, "Temocillin and meropenem to discriminate resistance mechanisms leading to decreased carbapenem susceptibility with focus on OXA-48 in Enterobacteriaceae", Clin Microbiol Infect, 19, pp.E230~E232 (2013)
- Findlay J, "OXA-48-like carbapenemases in the UK : an analysis of isolates and cases from 2007 to 2014", J Antimicrob Chemother, 72, pp.1340~1349 (2017)
- Jamal WY, "Emergence of new sequence type OXA-48carbapenemase-producing Enterobacteriaceae in Kuwait", Microb Drug Resist, 21, pp.329~334 (2015)
- Balkan II, "Blood stream infections due to OXA-48-like carbapenemaseproducing Enterobacteriaceae : treatment and survival", Int J Infect Dis, 26, pp.51~56 (2014)
- Voulgari E, "Outbreak of OXA-48 carbapenemase-producing Klebsiella pneumoniae in Greece involving an ST11clone", J Antimicrob Chemother, 68, pp.84~88 (2013)
- Cuzon G, "Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France", Antimicrob Agents Chemother, 55, pp.2420~2423 (2011)
- Koroska F, "Comparison of phenotypic tests and an immunochromatographic assay and development of a new algorithm for detection of OXA-48-like carbapenemases", J Clin Microbiol, 55, pp.877~883 (2017)
- Guzmán-Puche J, "Characterization of OXA-48-producing Klebsiella oxytoca isolates from a hospital outbreak in Tunisia", J Glob Antimicrob Resist, 24, pp.306~310 (2021)
- Girlich D, "CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli", Antimicrob Agents Chemother, 53, pp.832~834 (2009)
- Alonso N, "Molecular characterisation of acquired and overproduced chromosomal blaAmpC in Escherichia coli clinical isolates", Int J Antimicrob Agents, 47, pp.62~68 (2016)
- Rivera-Izquierdo M, "OXA-48 carbapenemase-producing Enterobacterales in Spanish hospitals: An updated comprehensive review on a rising antimicrobial resistance", Antibiotics(Basel), 10, pp.89~ (2021)
- Kolenda C, "Evaluation of the new multiplex immunochromatographic O. K. N. V. K-SeT assay for rapid detection of OXA-48-like, KPC, NDM, and VIM carbapenemases", J Clin Microbiol, 56, pp.e01247-18~ (2018)
- Boutal H, "A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP-and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae", J Antimicrob Chemother, 73, pp.909~915 (2018)
- Hernández-García M, "Intestinal co-colonization with different carbapenemase-producing Enterobacterales isolates is not a rare event in an OXA-48 endemic area", EClinicalMedicine, 15, pp.72~79 (2019)
- Saïdani M, "Emergence of carbapenemresistant OXA-48 carbapenemase-producing Enterobacteriaceae in Tunisia", J Med Microbiol, 61, pp.1746~1749 (2012)
- Skalova A, "Molecular characterization of OXA-48-likeproducing Enterobacteriaceae in the Czech Republic and evidence for horizontal transfer of pOXA-48-like plasmids", Antimicrob Agents Chemother, 61, pp.e01889-16~ (2017)
- Stewart A, "Treatment of infections by OXA-48-producing Enterobacteriaceae", Antimicrob Agents Chemother, 62, pp.e01195-18~ (2018)
- Katip W, "Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients", Pharmaceutics, 14, pp.31~ (2021)
- Samal S, "Polymyxin monotherapy vs. combination therapy for the treatment of multidrug-resistant infections : A systematic review and metaanalysis", Indian J Crit Care Med, 25, pp.199~206 (2021)
- Hou SY, "Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae : A systematic review and meta-analysis", J Glob Antimicrob Resist, 23, pp.197~202 (2020)
- Katip W, "Effectiveness and nephrotoxicity of loading dose colistinmeropenem versus loading dose colistin-imipenem in the treatment of carbapenem-resistant Acinetobacter baumannii infection", Pharmaceutics, 14, pp.1266~ (2022)
- Katip W, "A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity scorematched analysis", Antibiotics(Basel), 9, pp.647~ (2020)
- Wanla W, "Effects of an antimicrobial restriction system on appropriate carbapenem use in a hospital without infectious diseases consultation", Int J Gen Med, 10, pp.443~449 (2017)
- "Epidemiological alert: Emergence and increase of new combinations of carbapenemases in Enterobacterales in Latin America and the Caribbean - 22 October 2021"[URL]